丙戊酸钠致1例血小板减少及低纤维蛋白原血症的药学监护及文献复习  

Pharmaceutical care and literature review of a case of thrombocytopenia and hypofibrinogenemia caused by sodium valproate

作　　者：谢辉平 谢宁 任金妹 XIE Huiping;XIE Ning;REN Jinmei(Department of Pharmacy,Qingpu Branch of Zhongshan Hospital,Fudan University,Shanghai 201700,China)

机构地区：[1]复旦大学附属中山医院青浦分院药剂科,上海201700

出　　处：《上海医药》2024年第11期103-106,共4页Shanghai Medical & Pharmaceutical Journal

基　　金：上海市青浦区第五轮医苑新星项目(YY2023-9);上海市青浦区第五轮学科带头人项目(XD2023-9);上海市青浦区第五轮领先学科项目(LX2023-8);复旦大学附属中山医院青浦分院第二轮亚专科建设项目(YZK2023-04)。

摘　　要：通过分析1例高龄患者在使用丙戊酸钠(VPA)治疗癫痫后出现的血小板(PLT)减少和低纤维蛋白原(FIB)血症的情况,探讨了老年癫痫患者在使用VPA治疗时可能出现的血液系统毒性反应,以及多药联用对药物安全性的影响。在治疗过程中,药师根据患者的具体情况建议调整了VPA的剂量,同时密切监测了患者的血常规和凝血功能指标。本病例强调了药师在临床治疗中对药物不良反应识别和处理能力的重要性,同时利用专业知识进行分析和监护,提高患者用药安全性。To explore the potential hematologic toxicity in elderly epilepsy patients treated with sodium valproate(VPA)and the impact of polypharmacy on medication safety by analysis of the situation of thrombocytopenia(PLT reduction)and hypofibrinogenemia(FIB reduction)in an elderly patient following the treatment of epilepsy with VPA.During the treatment,the pharmacists recommended a adjustment of the dose of VPA according to the specific condition of the patient,and closely monitored the patient’s blood routine and coagulation function indicators.This case emphasizes the importance of pharmacists’ability to identify and manage adverse drug reactions in clinical treatment,and at the same time highlights the use of their professional knowledge to analyze and monitor adverse drug reactions to improve the safety of patients’medication.

关 键 词：丙戊酸钠 血小板 纤维蛋白原 不良反应 药学监护 

分 类 号：R971.6[医药卫生—药品]